Merck ’s MRK stock has declined around 10.3% in the past three months, losing almost $32 billion of its market value.

Charlie CY Yang, an analyst from Bank of America Securities, maintained the Buy rating on Merck & Company (MRK – Research Report).

The potential of mRNA vaccines was established during the COVID-19 pandemic. Now, a new wave of candidates could soon hit the ...

Moderna should not be left off the list of interesting investment opportunities, as the company has one of the best pipelines ...

The US Department of Agriculture (USDA) has taken a significant step towards the approval of an H5N1 avian flu vaccine for ...

This summary covers significant updates in the health sector, including US Senator Bernie Sanders' push for cheaper generic ...

Pfizer Inc (NYSE: PFE) presented positive trial data for experimental drug designed for patients suffering from cancer ...

With the stock now more than cut in half from its 52-week high, the company recently laid out a plan for its business at its ...

Deep-pocketed investors have adopted a bullish approach towards Merck & Co MRK, and it's something market players shouldn't ...

Along with breast cancer, cervical cancer is among the most feared cancer diagnoses for women around the world.

Moderna’s move into personalised cancer therapy continues to proceed at a rapid pace, with Merck & Co-partnered melanoma vaccine mRNA-4157 heading for a pivotal phase 3 programme after a phase ...